How covid-19 is accelerating the threat of antimicrobial resistance

Hsu, Jeremy

doi:10.1136/bmj.m1983

Cited by 231 publications

(234 citation statements)

References 6 publications

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…Research, Society andDevelopment, v. 9, n. 9, e841997245, 2020 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v9i9.7245 12 O uso freqüente de antibióticos de amplo espectro para COVID-19 pretendidos para eliminar uma ampla gama de bactérias podem estimular a resistência antimicrobiana (RAM) através do uso excessivo. Tais achados dão suporte às preocupações dos pesquisadores de que o aumento do uso de antibióticos durante a pandemia poderia aumentar a ameaça a longo prazo da RAM (Hsu, J. (2020).…”

Section: Superinfecções Bacterianas Em Pacientes Com Covid-19unclassified

O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos

Vellano

Paiva²

2020

RSD

View full text Add to dashboard Cite

Atualmente, o COVID-19 está ocasionando uma preocupante emergência de saúde pública e a mortalidade está aumentando rapidamente em todo o mundo. No momento atual da pandemia, apesar de ter havido muita persistencia para diagnosticar vários pacientes com sintomas ou contatos próximos, não existe diretrizes definitivas para a abordagem terapêutica inicial para eles e, portanto, muitos pacientes estão morrendo devido a uma reação imunológica hiperinflamatória rotulado como "tempestade de citocinas".O uso de antimicrobianos no tratamento e prevenção de COVID-19, causado pelo novo coronavírus SARS-CoV-2, está em ascensão.Antibióticos usado para tratar infecção por estafilococos, anteriormente mostrou eficácia para inibir o primeiro estágio do ciclo viral do MERScoronarivus em células humanas. Essa atividade é conservada no SARS-Cov-2, colocando esse emprego como um tratamento potencial para pacientes com esse vírus. Foi realizado uma revisão da literatura utilizando os bancos de dados PubMed, LILACS e Scielo, com os termos “Covid”, “antibiotico, “terapia “e “resistencia microbiana e equivalentes em inglês. Nesta revisão, discutimos alguns pontos importantes dedicados ao manejo de pacientes com COVID-19 em uso de antibioticos.

show abstract

Section: Superinfecções Bacterianas Em Pacientes Com Covid-19unclassified

O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos

Vellano

Paiva²

2020

RSD

View full text Add to dashboard Cite

show abstract

“…In 2019, the United States recorded 2.8 million antibiotic-resistant infections, resulting in over 35,000 deaths (1). The recent surge in antibiotic use in the setting of the COVID-19 pandemic portends an acceleration of the antibiotic resistance threat (1,2). Staphylococcus aureus is a formidable human pathogen that causes a wide variety of invasive and life-threatening infections.…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB

Mikati¹,

Miller²,

Osbourn

et al. 2020

Preprint

View full text Add to dashboard Cite

With the rising prevalence of multidrug-resistance, there is an urgent need to develop novel antibiotics. Many putative antibiotics demonstrate promising in vitro potency but fail in vivo due to poor drug-like qualities (e.g. serum half-life, oral absorption, solubility, toxicity). These drug-like properties can be modified through the addition of chemical protecting groups, creating “prodrugs” that are activated prior to target inhibition. Lipophilic prodrugging techniques, including the attachment of a pivaloyloxymethyl group, have garnered attention for their ability to increase cellular permeability by masking charged residues and the relative ease of the chemical prodrugging process. Unfortunately, pivaloyloxymethyl prodrugs are rapidly activated by human sera, rendering any membrane permeability qualities absent during clinical treatment. Identification of the bacterial prodrug activation pathway(s) will allow for the development of host-stable and microbe-targeted prodrug therapies. Here, we use two zoonotic staphylococcal species, S. schleiferi and S. pseudintermedius, to establish the mechanism of carboxy ester prodrug activation. Using a forward genetic screen, we identify a conserved locus in both species encoding the enzyme hydroxyacylglutathione hydrolase (GloB), whose loss-of-function confers resistance to carboxy ester prodrugs. We enzymatically characterize GloB and demonstrate that it is a functional glyoxalase II enzyme, which has the capacity to activate carboxy ester prodrugs. As GloB homologs are both widespread and diverse in sequence, our findings suggest that GloB may be a useful mechanism for developing species-or genus-level prodrug targeting strategies.

show abstract

“…This might be even further aggravated by the current wide use of antibiotics for the treatment of COVID-19 patients, in an attempt to prevent and treat bacterial superinfections. This is why early on US-American physicians highlighted the importance of thoughtful antibiotic stewardship in general and in treating COVID-19 patients in particular [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Review of therapeutic options for infections with carbapenem-resistant Klebsiella pneumoniae

Bandick

Mousavi

Bereswill

et al. 2020

EuJMI

View full text Add to dashboard Cite

Infections with multi-drug resistant (MDR) bacteria including carbapenem-resistant Klebsiella pneumoniae are emerging worldwide but are difficult to treat with the currently available antibiotic compounds and therefore constitute serious threats to human health. This prompted us to perform a literature survey applying the MEDLINE database and Cochrane Register of Controlled Trials including clinical trials comparing different treatment regimens for infections caused by carbapenem-resistant K. pneumoniae. Our survey revealed that a combined application of antibiotic compounds such as meropenem plus vaborbactam, meropenem plus colistin and carbapenem plus carbapenem, resulted in significantly increased clinical cure and decreased mortality rates as compared to respective control treatment. However, further research on novel antibiotic compounds, but also on antibiotic-independent molecules providing synergistic or at least resistance-modifying properties needs to be undertaken in vitro as well as in large clinical trials to provide future options in the combat of emerging life-threatening infections caused by MDR bacteria.

show abstract

How covid-19 is accelerating the threat of antimicrobial resistance

Abstract: Healthcare responses to the novel coronavirus may be hastening another long looming public health threat, writes Jeremy Hsu

Cited by 231 publications

References 6 publications

O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos

O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos

Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB

Review of therapeutic options for infections with carbapenem-resistant Klebsiella pneumoniae

Contact Info

Product

Resources

About